Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Plasmid stability testing is essential for gene therapy CMC, assessing supercoiled topology integrity under various storage conditions. Supercoiled conformation directly impacts transfection efficiency, expression, and long-term stability.
Our service quantifies supercoiled proportion (HPLC/CGE), monitors topoisomers (supercoiled, open circular, linear), and performs forced degradation and long-term/accelerated studies. Creative Biogene offers stage-appropriate strategies – from early screening to GMP-aligned release testing for IND/BLA – delivering a complete data package for shelf-life assignment.
Plasmid DNA can exist in three major topological isoforms during production, purification, and storage, each with fundamentally different functional and stability characteristics:
| Topology | Structural Feature | Biological Significance | Stability Feature |
| Supercoiled (SC) | Covalently closed circular DNA with negative superhelical twists | Highest transfection efficiency, strongest expression activity in vitro/in vivo | Most stable, but susceptible to shear, temperature, and nucleases |
| Open circular (OC) | Covalently closed circular with a single-strand break | Significantly reduced transfection efficiency | Relatively stable, can further linearize |
| Linear (L) | Double-strand break, exposed ends | Functionally inactive | Least stable, easily degraded by exonucleases |
Studies have shown that supercoiled plasmid DNA can have 5-10 times higher transfection efficiency than the open circular form, while the linear form is almost completely inactive. Therefore, the supercoiled proportion is not only a key indicator of plasmid purity but also a direct surrogate marker for product functional potency.
Creative Biogene offers three technical routes for plasmid stability testing, flexibly selectable based on product stage and sensitivity needs.
Ion Exchange HPLC (IEX-HPLC)
Anion exchange chromatography separates topological isoforms. The supercoiled form has the most compact conformation and lowest negative charge density, eluting first; the linear form elutes in the middle; the open circular form, with a loose conformation and exposed negative charges, elutes last. Peak area percentages are quantified by UV detection at 260 nm.
Capillary Gel Electrophoresis (CGE)
A capillary filled with a gel sieving medium separates plasmid DNA by size and conformation under an electric field. The supercoiled form migrates fastest due to its smallest volume; open circular and linear forms migrate more slowly. Laser-induced fluorescence detection (CGE-LIF) significantly improves sensitivity (detection limit down to pg level).
Agarose Gel Electrophoresis (AGE)
Plasmid DNA is electrophoresed in an agarose gel: supercoiled migrates fastest (lowest), open circular migrates slowest (highest), and linear is intermediate. Bands are quantified by gel imaging and densitometric scanning.
| Document | Relevant Section | Key Requirements |
| FDA CMC Guidance for Human Gene Therapy IND Applications (2020) | Section IV: Stability Testing | Requires submission of stability protocols and data, including evaluation of active ingredient stability during storage |
| ICH Q5C: Stability Testing of Biotechnological/Biological Products | Whole document | Provides a framework for stability testing of biotech products; requires stability-indicating methods, covering long-term and accelerated studies |
| USP <1040> | Plasmid DNA as Starting Material | Outlines quality considerations for plasmid as a starting material for cell and gene therapy, including supercoiled proportion testing |
| BioPhorum Industry Consensus | Plasmid Release Specifications | Recommends ≥80% supercoiled as a release reference standard; suggests CGE, HPLC, or AGE for quantitation |
Different regulatory agencies have varying expectations for the supercoiled proportion. The acceptance criteria should be set based on a risk assessment considering the product's mechanism of action, route of administration, clinical stage, and process capability.
HPLC and CGE are industry-standard methods for supercoiled quantification. Although not yet formalized as complete pharmacopoeial monographs, the underlying technologies—chromatography and electrophoresis—are pharmacopoeially recognized. These methods have been widely accepted by CDMOs and regulators for plasmid stability testing. For IND submissions, adequate method validation per ICH Q2 guidelines is sufficient to meet regulatory requirements.
Creative Biogene's approach combines industry-standard methods with stage-appropriate validation, ensuring both scientific rigor and regulatory acceptance.
For detailed technical discussions on stability testing strategies, method validation plans, or IND submission support for your product-specific stage, please contact the Creative Biogene technical team for customized solutions.
Q1: Is plasmid stability testing necessary at all product stages?
A: Yes. Starting from the IND submission, regulatory agencies require stability data to support product quality control during clinical trials. However, the depth of testing matches the stage – Phase I may accept limited batches (typically 2-3) and limited time points (e.g., 0, 3, 6 months); Phase III and BLA require a full data package (3 commercial scale batches with long-term stability data covering the proposed shelf life). Creative Biogene provides stage-matched testing solutions.
Q2: What is the minimum sample volume for supercoiled proportion testing?
A: HPLC requires approximately 5-20 μg of plasmid DNA per injection (depending on column capacity); CGE requires <1 μg (including replicates); AGE requires about 100-500 ng. We recommend submitting at least 50 μL of sample solution at ≥50 μg/mL to ensure sufficient material for potential retesting.
Q3: Why is the supercoiled proportion more important than concentration or purity?
A: Supercoiled proportion directly reflects structural integrity, the key determinant of functional activity. Concentration (A260) often remains stable during early degradation, while supercoiled to open circular conversion can occur early. Supercoiled plasmids have 5-10× higher transfection efficiency; a decrease in supercoiled proportion is an early warning of activity loss. This is why ICH Q5C requires stability-indicating methods – they must detect degradation trends, not just the total amount.
Q4: What to do when stability results exceed acceptance criteria?
A: Two steps: 1) Investigation – rule out lab causes (retest, check instrument, review integration). 2) If not analytical error, root cause analysis – storage temperature deviations, transport exposure, packaging integrity, batch differences. Actions: if isolated and not affecting quality, document and continue; if systemic degradation, reassess shelf life, adjust storage conditions, or optimize formulation. Document all OOS results and investigations.
Q5: Additional stability requirements for the plasmid used as mRNA transcription template?
A: Yes. Supercoiled proportion remains core – supercoiled gives higher quality templates. Additionally, linearized plasmid integrity (terminal integrity) directly affects IVT yield and mRNA quality. Monitor both: (1) topological stability of supercoiled plasmid during storage, and (2) degradation of linearized plasmid (end shearing, exonuclease degradation). Include capillary electrophoresis of linearized product in the stability protocol. Creative Biogene can design specialized protocols for mRNA template plasmids.
Copyright © 2026 Creative Biogene. All rights reserved.